Brokerages Update Recommendations on Key Stocks: Sun Pharma, LTIMindtree, NTPC and More
Sun Pharma, LTIMindtree, NTPC, Divi's Lab, Hindalco And More On Brokerages' Radar
Image: Ndtv
Brokerages are actively revising their recommendations on various sectors, including healthcare and utilities. Key updates include Sun Pharma's growth outlook, LTIMindtree's acquisition strategy, and NTPC's performance amidst competition. Analysts maintain mixed ratings across these stocks, reflecting cautious optimism.
- 01Kotak Securities maintains an 'Add' rating on Sun Pharmaceutical Industries with a target price of ₹1,960, citing a strong long-term growth outlook despite recent performance misses.
- 02HSBC maintains a 'Buy' rating on LTIMindtree, raising its target price to ₹5,250, highlighting the strategic acquisition of Randstad Technology and Consulting.
- 03Bernstein maintains an 'Outperform' rating on NTPC with a target price of ₹430, noting its reasonable valuation among utility stocks.
- 04Citi maintains a 'Buy' rating on Divi's Laboratories with a target price of ₹9,140, viewing recent softness as temporary and expecting strong revenue growth.
- 05CLSA raises target prices for Hindalco to ₹1,240, driven by strong performance in its Indian operations despite rising costs.
Advertisement
In-Article Ad
Brokerages are closely monitoring several key stocks in healthcare, utilities, and technology sectors, providing updated recommendations based on recent performance and future outlooks. Kotak Securities has maintained an 'Add' rating on Sun Pharmaceutical Industries with a target price of ₹1,960, despite a disappointing Q4FY26 performance. Analysts from HSBC have reiterated a 'Buy' on LTIMindtree, increasing the target price to ₹5,250, thanks to its acquisition of Randstad Technology and Consulting, which is expected to enhance operational capabilities. NTPC remains a focus for Bernstein, which maintains an 'Outperform' rating with a target of ₹430, citing its reasonable valuation and ongoing execution. Divi's Laboratories sees mixed reviews, with Citi maintaining a 'Buy' rating and a target of ₹9,140, indicating confidence in its growth despite recent challenges. Hindalco's performance has led CLSA to raise its target price to ₹1,240, reflecting strong results from its Indian operations. Overall, brokerages express cautious optimism as they navigate a challenging market environment.
Advertisement
In-Article Ad
The updates from brokerages could influence investor decisions and stock performance in the Indian market, particularly in the healthcare and utilities sectors.
Advertisement
In-Article Ad
Reader Poll
Which stock do you believe will perform best in the coming months?
Connecting to poll...
More about Sun Pharmaceutical Industries
Read the original article
Visit the source for the complete story.